fy2024earningspresentati

CO PY RI GH T © A BC EL LE RA FEBRUARY 27, 2025 FULL YEAR 2024 BUSINESS UPDATE

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. 2 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e

3 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e FULL YEAR 2024 RECAP Transitioning into a clinical-stage biotech. Completing Investments in Our Engine Building Internal Pipeline & Programs ● Put first 2 programs on track for Clinical Trial Application (CTA) submissions in Q2 2025 ● Advanced discovery pipeline of antibody drug programs with first-in-class or best-in-class potential ● Moved into new HQ ● Built Phase 1 clinical manufacturing and operations capabilities for launch in 2025 Reducing New Discovery Partnership Activity ● 2 new partnerships ● 1 partnership expansion in available liquidity to execute on our strategy~$840M

4 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Use our competitive advantage in antibody drug creation to build a pipeline of differentiated assets. STRATEGY

5 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Is there an opportunity for differentiation? Is there a clear development path? Is there a commercial opportunity with an unmet medical need? Do we like the science? Our platform supports multiple modalities including IgGs, ADCs and bispecifics. Our strategy is to look broadly for programs that have the highest potential ROI, without constraint by indication. We manage our portfolio and assess opportunities by asking the following questions: Pursue high-value opportunities across multiple indications and modalities. INTERNAL PIPELINE & PROGRAMS

6 CO PY RI GH T © A BC EL LE RA ● Potential first-in-class antibody in area of metabolic and endocrine conditions ● Expect differentiated safety profile vs small molecules ● Convenience and compliance with subcutaneous dosing schedule Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e ABCL635 Undisclosed Science DifferentiationCommercial Opp Development Path ● Pathway validated with small molecules ● High unmet need in large target population ● >$2B estimated market ● Clear clinical development path ● CTA* filing anticipated in Q2 2025 with safety and early efficacy data readout in 2026 * Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission INTERNAL PIPELINE & PROGRAMS

7 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e ● OX40L mechanism of action established in atopic dermatitis with a favourable safety profile ● High potential across multiple immunology and inflammation (I&I) indications (asthma, alopecia, HS, celiac etc.) ● Attractive pathway for development of combinations in I&I * Cantor Fitzgerald Estimate, September, 2024 ● Competitive space with two late stage programs targeting OX40L (amlitelimab) and OX40 (rocatilimab) ● ABCL575 expected to support Q12W or longer dosing schedule ● Atopic dermatitis is an $11B+* market, growing at over 25% ● Need for alternatives beyond IL-13 and IL-4/13 classes in both 1st line and 2nd line (more than 20%** of dupilumab patients discontinue) ● Potential of OX40L class across multiple indications is being evaluated ● Well-established clinical development path ● CTA*** filing anticipated in Q2 2025 with safety and PK in 2026 ** Spekhorst et al. JAMA Dermatol. 2022; 158(9): 1048 *** Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission ABCL575 OX40L Antagonist INTERNAL PIPELINE & PROGRAMS Science DifferentiationCommercial Opp Development Path

8 CO PY RI GH T © A BC EL LE RA MOLECULE TARGET THERAPEUTIC AREA STAGE ABCL635 Undisclosed GPCR or ion channel Metabolic & Endocrine Conditions ABCL575 OX40L Immunology & Inflammation Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e In 2025 we intend to submit CTAs* for our first 2 programs. * Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission CTA / IND-Enabling 2025 Q1 In progress CTA Submission 2025 Q2 Anticipated Phase I Readout 2026 Anticipated CTA / IND-Enabling 2025 Q1 In progress CTA Submission 2025 Q2 Anticipated Phase I Readout 2026 Anticipated 20+ discovery programs in the pipeline INTERNAL PIPELINE & PROGRAMS

9 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e In order to focus on our pipeline, we decreased new discovery partnership activity. new partnerships 2 AbbVie partnership expansion 1 Entered into first significant TCE partnership agreement based on T-Cell Engager platform: Entered into 3 partnership agreements in the first half of 2024: PARTNERING PORTFOLIO 2024 Partnering Activity T-Cell Engager Platform Activity partnership expansion 1

10 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Enter the clinic and initiate clinical manufacturing activities at new facility. ABCL635 Phase 1 clinical trials initiated in 2025 ABCL575 Phase 1 clinical trials initiated in 2025 Complete platform investments by the first half of the year Initiate activities at the new clinical manufacturing facility Nominate additional development candidate(s) for CTA-enabling studies 2025 PRIORITIES

11 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e We expect a number of key milestones in the next 18-24 months. CTA submissions anticipated in Q2 2025. If successful, initiation of Phase 1 clinical trials to follow: ● ABCL635 ● ABCL575 20+ internal programs in the pipeline: ● Expect steady flow of readouts on potentially first-in-class therapeutic antibodies Anticipate readout of Phase 1 clinical data: ● ABCL635 ● ABCL575 First 2 clinical data readouts in 2026 First 2 CTAs* & start of clinical trials in 2025 Intention to submit 1-3 INDs per year over next 5 years POTENTIAL MILESTONES * Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission

12 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 20 24 B us in es s U pd at e FULL YEAR 2024 FINANCIALS UPDATE

13 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e in total cash, cash equivalents, & marketable securities cumulative partner-initiated program starts with downstreams internal programs advanced into IND/CTA-enabling studies ~$650M 96 2 molecules in the clinic16 in available liquidity to execute on our strategy~$840M Continued progress on key business metrics and a strong cash position.

14 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e PARTNER-INITIATED PROGRAM STARTS WITH DOWNSTREAMS Cumulative # of MOLECULES IN THE CLINIC Cumulative # of Note: Showing year-end figures. Historical results are not necessarily indicative of future results. Notable Updates on Molecule This Quarter’s Update ABD-147 Advanced into Phase 1 trial Undisclosed (Trianni license) New, in Phase 1/2 trial GIGA-564 (Trianni license) New, in Phase 1 trial Continuing portfolio growth. MOLECULES IN THE CLINIC

15 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Partner-initiated programs continue to progress towards the clinic. PARTNER-INITIATED PROGRAMS WITH DOWNSTREAM PARTICIPATION*Cumulative # of *Excludes AbCellera-initiated and Trianni-license program. As of Dec 31, 2024. Historical results are not necessarily indicative of future results. 96 6 76 39 14 37 42 5 4 Understood to be Progressing In Progress AbCellera Leading or Co-Leading Work Partner Leading Work AbCellera Started Transferred to Partner Clinical Development Preclinical Development Discovery Not Expected to Progress Not Expected to Progress

16 CO PY RI GH T © A BC EL LE RA Large diversified exposure to next-gen antibody therapies. *As of December 31, 2024 AbCellera-Initiated Programs* started across these therapeutic areas27 100% human health n = 27 Partner-Initiated Programs with Downstream Participation* started are diversified across these therapeutic areas 96 91% human health: target antigen known n = 87 9% animal health n = 9 21% neurology 6% infectious disease 5% ophthal- mology 4% other 17% immunology & inflammation 47% oncology 30% oncology & immunology T-cell engagers 56% undisclosed GPCRs & ion channels n = 8 n = 15 infectious disease pandemic response 4%10% undisclosed other n = 3 n = 1 Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e

17 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Operating expenses reflect investments, predominantly in R&D; partly offset by $29M in revenue. Operating Expenses USDRevenue USD 20242023 $175.7M $167.3M -$8.4M 20242023 $14.2M $12.8M -$1.4M 20242023 $61.0M $72.7M +$11.7M RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMINLICENSING RESEARCH FEES MILESTONES 2024 $26.3M 2023 $38.0M $28.8M $1.5M $1.0M$35.6M Milestones Licensin g Research fees

18 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Net loss of $163M; equivalent to ($0.55) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED 2023 2024 ($146.4M) ($162.9M) Post-production ❑ Move “Q” labels down

19 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Approximately $653M in total cash, equivalents, and marketable securities. Cash Flows USD * Restricted cash (including restricted cash in other assets) ($51M) Other INVESTING FINANCING FX $469M Marketable Securities $156M Cash & Equivalents $27M* $627M Marketable Securities $173M Marketable Securities (net) OPERATINGDec 31, 2023 $27M* $133M Cash & Equivalents $788M ($109M) $121M $13M ($3M) $653M Dec 31, 2024